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Dramatic changes in the epidemiology of Clostridium difficile infections have
been reported from the western world in the past decade. The proportion of severe
cases is significantly elevating and clinicians now have to contend with the problem of
additional and more frequent episodes of recurrences including an upward trend in the
mortality rate. This situation led us to investigate the possibility of the fecal microbiota
transplantation (FMT). An amount of 100 ml of fecal microbiota solution was instilled
into a nasojejunal (NJ) tube in 16 cases and into a nasogastric (NG) tube in 44 cases. In
all of the cases, where the solution was instilled via nasojejunal tubes, the symptoms
resolved within 24 h. We did not note any recurrences in this group. When the material
was flushed in through nasogastric tubes, the symptoms resolved in 39 (88.64%) cases
within 24 h. In this group, we have experienced a recurrent episode of C. difficile
infection in five (11.36%) cases. Three of them were cured with a second transplan-
tation. We have found that in our practice the upper gastrointestinal tract methods had
the primary cure rate of 91.67%, whereas the secondary cure rate is 96.67%. When we
compared the NJ and NGmethods, we have found that the differences in the outcomes
are not significant statistically (p= 0.3113 using Fisher’s exact probability test). In
conclusion, FMT proved to be very effective, particularly in recurrent infections and in
cases where conventional treatment had failed.
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Introduction
Clostridium difficile, a Gram-positive, obligate anaerobic, spore-forming
bacillus, was first isolated from the feces of healthy neonates in 1935 [1]. It was
initially believed to be non-pathogenic, but in 1978, C. difficile was identified as
the leading cause of antibiotic-associated diarrhea and a major cause of
pseudomembranous colitis [2]. The epidemiology of C. difficile infection (CDI)
has recently undergone a dramatic change worldwide. Between 1996 and 2003,
the prevalence of CDI in the USA doubled, reaching 61 per 100,000 [3], and the
rate of CDI listed as any diagnosis of hospitalized patients rose from 3.82 per
1,000 discharges in 2000 to 8.75 per 1,000 discharges in 2008 [4]. Simulta-
neously, greater numbers of severe and lethal cases or treatment failures
were reported from Quebec (Canada) and in the USA [5]. In Pécs, a city in
southwest Hungary, the incidence and mortality (12%) of CDI have increased
since 2008. Considerable effort has been devoted to the search for new strategies
of recurrent CDI. It was recently suggested that fecal microbiota transplantation
(FMT) is a relatively safe, low cost, and effective solution of CDI that fails to
resolve in response to traditional antibiotic regimens, especially in recurrences
[6]. Although the first transplantation in humans was reported in 1958 [7],
the idea of the transplantation of viable gastrointestinal (GI) microbes from
one individual to another is much older. It was probably the Italian anatomist
Fabricius Aquapedente who first described this method in animals, as
“transfaunation” [8].
Materials and Methods
Patient indications
However, there is no clear evidence as to the exact indications of FMT, but
the recently published international literature strongly indicates that it is an
effective option in recurrent CDI, primarily for those cases where conservative
therapeutic solutions have failed to eliminate the infection [6, 9, 10]. Study
participants were recruited based on criteria of FMT, published in consensus
guidelines [11], and adapted to local circumstances. Subjects with refractory or
recurrent active CDI were included. Major exclusion criteria included acute
abdomen, signs of perforation, recent operation with the opening of the upper
or lower GI tract, upper GI tract hemorrhage, signs of ileus, and uncontrollable
vomiting.
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Donor determination and screening
Proper donor screening is essential to avoid the transmission of communi-
cable diseases. Each donor served as a volunteer and was initially screened by
means of a questionnaire to exclude potentially high-risk individuals (e.g., drug
use, unprotected sexual behavior or a history of extensive travel, illness, or
antibiotic intake in the past 6 months). Donated feces were screened for parasites,
entero-pathogenic bacteria, and C. difficile, whereas the serum was screened for
HIV-1 and HIV-2, EBV, CMV, hepatitis A, B, and C, and Treponema pallidum.
Preparation of the sample
Neither the exact amount of donated feces needed for the transplantation nor
the volume of fluid has been clearly determined. Meta-analyses suggest that a
larger volume of feces will increase the success rate and reduce the relapse rate,
since ideal clinical results seem to be greatest (97%) when more than 500 ml of
suspension is transferred (while the resolution rate was found 80% when less than
200 ml is flushed in), and four times higher relapse rates have been reported when
less than 50 g of stool is donated [6, 8]. Most authors recommend the use of normal
saline, but some have used milk in view of the finding in which patients with
recurrent CDI excrete lower amounts of short-chain fatty acids into their feces as
compared to healthy controls [12, 13].
We used freshly prepared transplant material, originated from a relative or a
household member of the patients in each of the cases. The donated feces
were collected and transported to our department on the day of the planned
FMT. A 60-g sample was homogenized in a mortar and suspended in 200 ml of
normal saline (0.9%). The suspension was then filtered through 4 × 4 cm sheets of
sterile gauze into another container, and 100 ml of the filtrate was absorbed into a
syringe. Entire steps of the preparation were performed in a laminated flow box,
and sterile devices were employed. Within 6 h following the collection of the feces
by the donor, the solution was infused into the patient.
Recipient preparation
In our department, when the condition of the patient permitted, antibiotic
administration was halted 4 days prior to the procedure. In serious cases, this
period was reduced to 1 day. In each case, thorough purging was applied on the
day prior to the intervention, in order to increase the success of the procedure, by
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flushing away residual feces, antibiotics, toxins, C. difficile bacteria, and spores to
the maximum attainable extent. The patients consumed nothing from midnight,
and in the morning before the procedure, they received a double dose of proton
pump inhibitor (PPI) intravenously. This increases the chances of survival of the
transplanted flora by reducing the gastric acid output. One hour prior to the
transplantation, 20 mg of metoclopramide was administered intravenously, to
prevent vomiting and to facilitate bowel movement in order to promote the
delivery of the transplantation material to the colon.
FMT delivery
The first reported FMT was achieved via a retention enema [7]. Since then,
three main types of FMT delivery have been developed. Clinicians tend to prefer
lower GI tract delivery, which can be performed in a highly effective way [14, 15].
Upper GI tract delivery methods also seem to be effective and time efficient
according to some studies [16–18]. Each technique has its advantages and
disadvantages and in the end, the choice of the optimal procedure should be a
patient-centered decision, based on both the wishes of the patient and the clinical
aspects, e.g., the patient’s general condition, the available equipment at site, and
skills and previous experiences of the medical staff.
Recently published results led us to use upper GI delivery methods,
including nasoduodenal (ND) and nasogastric (NG) tubes [19, 20]. Before the
NG tube was inserted, the distance was measured from the tip of the patient’s nose,
loop around their ear, and then down 5 cm below the xiphoid process. The tube
was then marked at this level to ensure that the tube has been inserted far enough
into the patient’s stomach. The end of the plastic tube was lubricated (anesthetic
spray have been applied before the insertion) and inserted into one of the patient’s
anterior nares. The tube was directed straight toward the back of the patient as it
moves through the nasal cavity and down into the throat. When the tube enters the
oropharynx, the patients were asked to mimic swallowing or some amount of
water was given to them to sip through a straw, and the tube continues to be
inserted as the patient swallows. To verify proper placement, air was injected into
the tube; if it was detected in the stomach by auscultation, the tube was declared in
the correct position.
The NJ feeding tube was placed by one skilled doctor. Some gastro-
enterologists were also involved in the fluoroscopy. Additional sedation was not
required for fluoroscopic tube placement. A portable C-arm fluoroscope was
positioned over the supine patient’s abdomen. The timing of the procedure began
when the feeding tube entered the nares. When the tube was advanced to
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50–55 cm, its position was evaluated by intermittent fluoroscopy. The operators
rotated the feeding tube to facilitate passage to the pylorus. Fluoroscopy was used
intermittently or continuously as needed. When the tip of the feeding tube was
beyond the pylorus, it was gently advanced as far as possible. Placement
of the tube beyond the third portion of the duodenum was preferred. Finally,
a fluoroscopic print was obtained after 10–15 ml of meglumine diatrizoate had
been injected into the feeding tube.
Cure rate
We defined the primary cure rate as the percentage of cases in which the
symptoms resolved without recurrence within 6 weeks after the FMT, and the
secondary cure rate as the percentage of cases in which the symptoms resolved
after a second FMT [14]. IDSA/SHEA guidelines do NOT recommend C. difficile
testing in patients who do not have symptoms, because patients can be colonized
with C. difficile and not develop disease [11, 21].
Results
Demographic data
We performed FMT on a total of 60 patients, of whom 37 (61.67%) were
females. The mean age was 71.48 years, including a range from 26 to 88 years of
age. The average number of recurrent infections was 2.24 (range: 0–8). In 40 cases
(66.67%), the patients exhibited a severe infection during the transplantation
(Table I).
Clinical outcomes
In all 16 initial cases, where the solution was instilled through ND tubes, we
noted that diarrhea had stopped within 24 h, as did all of the other symptoms. No
recurrences occurred in this group. Following 1 week, it should be noted that
diarrhea resumed in the case of a 70-year-old female who previously had eight
microbiologically proven recurrences of CDI. Clostridial toxins could not be
detected and the bacterium could not be cultured from her stools after the FMT.
Detailed gastroenterological examinations subsequently revealed a late onset of
irritable bowel syndrome in this patient.
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When the inoculum was flushed in through NG tube, all the patients
improved within 48 h. In 88.64% (39) of these cases, we did not experience
any recurrences during 6 weeks; however, in five cases (11.36%), microbiologi-
cally confirmed CDI recurred. These patients were aged (over 75 years), with a
severe underlying condition, and it is important to note that one of them had
previously been given antibiotics to treat his urinary tract infection caused by
multidrug-resistant organisms. After the second transplantation, three of the
five patients were cured, and thus the secondary cure rate in this subgroup has
been found to 95.45%. In our hands, the overall primary cure rate of upper GI tract
FMT was 91.67%, whereas the overall secondary cure rate was 96.67%.
It is important to note the recurrence rate appeared to be lower when the
solution was instilled through ND tubes. Although the difference (p= 0.3113,
using Fisher’s exact probability test) between the two groups was statistically not
significant, we consider it to be clinically important.
Nausea was observed in one case, but could be controlled with vitamin B6
andmetoclopramid. No other side-effects or reactions were detected, and therefore
we cannot support the view in which the “yuck” factor is a relevant obstacle.
Discussion
Treating CDI and mainly recurrent CDI are the therapeutic challenges for
patients and physicians. Current treatment options include repeated or prolonged
courses of antibiotics with limited success rates, and there is lack of alternative
therapeutic options (immunoglobulin preparations from vaccinated cows and
probiotics). Participants of this study were recruited from the patients referred
Table I. Demographic and clinical characteristics of the patients
Characteristics
FMT via ND sonde
(N= 16)
FMT via NG sonde
(N= 44)
Median age (years; range) 67.8 (35–88) 76.7 (51–89)
Number of females 9 (56.2) 28 (63.64)
Median number of recurrences of CDI (range) 2.7 (1–8) 1.75 (0–3)
Number of previous failure of vancomycin therapy (%) 11 (68.75) 30 (68.18)
Number of previous antibiotic use (%) 16 (100) 37 (84.09)
Number of use of proton pump inhibitor (%) 11 (68.75) 26 (59.09)
Median stool frequency/24 h (range) 7.2 (5–15) 5.2 (5–10)
Median leukocyte count/mm3 (range) 7,900
(2,900–27,000)
12,000
(5,600–19,700)
Median creatinine level μmol/L (range) 80.75 (45–173) 109.12 (37–270)
Note: FMT: fecal microbiota transplantation; CDI: Clostridium difficile infection; ND: nasoduodenal;
NG: nasogastric.
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to our ward between April 2013 and September 2015. All of them suffered from
refractory or recurrent episode of CDI. Indications and contraindication were
based on the recommendations of consensus guidelines and were adapted to local
circumstances [22].
One of the modes of performing FMT available today is upper GI tract
administration including NG tubes, duodenal tubes, and endoscopy/gastroscopy.
According to the recorded data, upper GI tract FMT requires smaller volumes of
fecal suspensions, and it also has a high cure rate [20, 21]. We prefer to use NG
tubes in our practice, because it has the advantage that it requires less patient
preparation, clinical time, and less patient inconvenience and cost than other routes
of administration. This method does not require the specialized skills of endo-
scopic procedures and it can be performed at the patients’ bedside. Each patient
was given a double dose of PPI intravenously at least 2 h prior to the procedure.
This increases the chances of survival of the transplanted flora by reducing the
gastric acid output. One hour prior to the transplantation, 20 mg of metoclopra-
mide was administered intravenously, to prevent vomiting and to facilitate bowel
movement in order to promote the delivery of the transplantation material to the
colon. However, in order to maximize the success rate, we decided to perform
FMT via ND route in those 16 cases (26.67%), where patients still complained of
symptoms of gastroesophageal reflux disease, despite taking double dose of PPI
regularly.
We used freshly prepared samples from healthy adults who were household
members or close relatives of the patients in each of the correlating case.
Unfortunately, a lot of patients did not have a relative, who could have been
suitable as a donor.
All our patients were hospitalized and discharged 3 or more days after FMT.
Possible adverse events were provoked by the medical staff of our ward based on a
self-report of the patients. Fever, GI symptoms, headache, fatigue, and rash were
the main symptoms evaluated. No serious adverse events or recurrences were
observed. No patient vomited within 24 h of administration. Mild adverse events,
e.g., bloating, abdominal cramp, and nausea were reported in just one case (1.67%).
In our hands, the overall primary cure rate of upper GI tract FMT was
91.67%, whereas the overall secondary cure rate was 96.67%.
Although we experienced an excellent clinical outcome, it is important to
note that this study has major limitations. The design of a multicentrical,
randomized study involving larger number of patients and with active comparators
should be considered in the future. The other major limitation is the problem of
long-term follow-up. All study participants were contacted through phone 6 weeks
and 3 months after the FMT. They were asked to complete a short questionnaire
concerning on their bowel movement, abdominal pain, and general well-being,
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recurrent episode of CDI, antibiotic intake since FMT, and newmedical conditions
occurring since FMT. No new medical conditions were reported. However, it is
important to note that these answers were not confirmed by a healthcare
professional (e.g., general practitioner or a nurse), except those (17 patients;
28.33%) who were inhabitants of a healthcare facility for elderly. No control stool
tests were performed. In order to evaluate the long-term efficacy (6 or 12 months),
additional interviews will be required.
Conclusions
FMT via upper GI tract has a high cure rate nearing 100%, and it is reported
safe that supports the viability of its use. We have to note, due to a lack of clinical
trials, it is only offered to patients with two or more relapses, and it remains as a
last rescue therapy. It is clear that further investigations are required to determine
its place in our therapeutic arsenal and the best protocol to perform FMT.
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